KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial.

Scott Kopetz, Takayuki Yoshino, Eric Van Cutsem, Cathy Eng, Tae Won Kim, Harpreet Singh Wasan, Jayesh Desai, Fortunato Ciardiello, Rona Yaeger, Timothy S Maughan, Elena Beyzarov, Xiaoxi Zhang, Graham Ferrier, Xiaosong Zhang, Josep Tabernero

Nat Med 31(3) 901-908

PMID39863775
PMCIDPMC11922750
DOI10.1038/s41591-024-03443-3
发表日期2025-01-25
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

Encorafenib + cetuximab (EC) is approved for previously treated BRAF V600E-mutant metastatic colorectal cancer (mCRC) based on the BEACON phase 3 study. Historically, first-line treatment of BRAF V600E-mutant mCRC with chemotherapy regimens has had limited efficacy. The phase 3 BREAKWATER study investigated EC+mFOLFOX6 versus standard of care (SOC) in patients with previously untreated BRAF V600E mCRC. The dual primary endpoint of progression-free survival is event driven; data were not mature at data cutoff. BREAKWATER met the other dual primary endpoint of objective response rate, demonstrating significant and clinically relevant improvement in objective response rate (EC+mFOLFOX6: 60.9%; SOC: 40.0%; odds ratio, 2.443; 95% confidence interval (CI): 1.403-4.253; 99.8% CI: 1.019-5.855; one-sided P = 0.0008). Median duration of response was 13.9 versus 11.1 months. At this first interim analysis of overall survival, the hazard ratio was 0.47 (95% CI: 0.318-0.691; repeated CI: 0.166-1.322). Serious adverse event rates were 37.7% versus 34.6%. The safety profiles were consistent with those known for each agent. BREAKWATER demonstrated a significantly improved response rate that was durable for first-line EC+mFOLFOX6 versus SOC in patients with BRAF V600E mCRC. ClinicalTrials.gov identifier: NCT04607421 .

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Fig. 3

Fig. 3. Overall survival. Hazard ratio repeated CI: 0.166–1.322.

OS

overall survival

Fig. 3 · Panel OS

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel OS 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 2:extreme jump曲线 2:off origin start曲线 2:extreme upward reversal
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1. Patient disposition. CAPOX, oxaliplatin and capecitabine; EC, encorafenib and cetuximab; mFOLFOX6, oxaliplatin, leucovorin and 5-FU; FOLFOXIRI, irinotecan, oxaliplatin, leucovorin and 5-FU; mCRC, metastatic colorectal cancer; SOC, standard of care. a One participant who was randomized to the EC+mFOLFOX6 arm (but never treated) was inadvertently entered as withdrawal by subject on the screening case report form page. b Following closure of the EC arm, randomization was 1:1 to the EC+mFOLFOX6 and SOC arms.
非 KM Figure
Fig. 2Fig. 2. Subgroup analyses of confirmed objective response rate by blinded independent central review. Odds ratios (center) are presented with 95% CI (error bars). EC+mFOLFOX6, encorafenib and cetuximab plus oxaliplatin, leucovorin and 5-FU. a Percentages were calculated based on the number of participants in the objective response rate subset of all randomized patients in each treatment group. b Objective response rate calculated based on the number of participants in the objective response rate subset of all randomized patients within each treatment group and subgroup. The odds ratio was estimated using the Mantel–Haenszel method. The exact CI was calculated.
非 KM Figure